Sponsor or institution

Clinical trials and research at Beijing GoBroad Hospital

• 27Clinical trials
• 1Country

Newest trials

All recruiting trials (27)

• XH001 with neoantigen vaccine–primed tumor-specific T cells for advanced gastrointestinal cancer

  This trial tests whether combining XH001 injections with T cells activated by a tumor neoantigen vaccine is safe and can shrink tumors or extend life in adults with advanced gastrointestinal cancer.

  Recruiting Phase 1 Beijing GoBroad Hospital · Beijing · NCT07329894

• TC-G203 treatment for GPC3-positive advanced solid tumors

  This trial will test a single-dose TC-G203 cell therapy to see if it is safe and helps adults with GPC3-positive recurrent or metastatic solid tumors who have already tried other treatments.

  Recruiting Early Phase 1 Beijing GoBroad Hospital · Beijing, Beijing Municipality and 1 other locations · NCT07242417

• CT041 after first-line treatment for CLDN18.2-positive advanced gastric or gastroesophageal junction cancer

  This study will test CT041, an autologous CLDN18.2-targeted CAR T-cell treatment, for people with advanced gastric or gastroesophageal junction adenocarcinoma after completing first-line therapy.

  Recruiting Beijing GoBroad Hospital · Beijing · NCT07179484

• OL-CD19-GDT CAR‑T for relapsed or refractory systemic sclerosis and primary Sjögren's syndrome

  This trial will try the CAR‑T therapy OL‑CD19‑GDT in adults whose systemic sclerosis or primary Sjögren's syndrome has relapsed or not responded to other treatments to see if it is safe and helps.

  Recruiting Phase 1 Beijing GoBroad Hospital · Beijing · NCT07167537

• Safety testing of STR-P004 in adults with relapsed or refractory autoimmune diseases

  This study will try multiple doses of STR-P004 to see if it's safe, tolerated, and how it behaves in adults whose autoimmune disease has relapsed or not responded to treatment.

  Recruiting Beijing GoBroad Hospital · Beijing · NCT07143617

• Dual CD19/CD20 cell therapy for relapsed or refractory B‑cell non‑Hodgkin lymphoma

  This trial will try a single infusion of LUCAR‑E9D or LUCAR‑E9K — engineered cells that target CD19 and CD20 — to see if they are safe and help adults with relapsed or refractory B‑cell non‑Hodgkin lymphoma.

  Recruiting at 3 sites Early Phase 1 Beijing GoBroad Hospital · Hefei and 2 other locations · NCT07093411

• Nanobody CD5 CAR‑T for relapsed or refractory CD5‑positive T‑cell cancers

  This will test a CD5-targeted CAR‑T cell treatment using patients' own or donor-derived cells to try to help people with relapsed or refractory CD5+ T‑cell leukemias and lymphomas.

  Recruiting at 3 sites Phase 1/2 Beijing GoBroad Hospital · Beijing, Beijing Municipality and 3 other locations · NCT07070323

• CD5 CAR T-cell therapy for relapsed or refractory T-cell lymphoma

  This trial tries CD5 CAR T-cell therapy, using either the patient's own cells or donor cells, and may bridge to stem-cell transplant for people 14–70 with relapsed or refractory T-cell lymphoma.

  Recruiting at 3 sites Phase 1/2 Beijing GoBroad Hospital · Beijing and 2 other locations · NCT07022964

• Dual-target BCMA and GPRC5D CAR-T for relapsed/refractory multiple myeloma with extramedullary disease

  This will try a CAR-T cell treatment that targets both BCMA and GPRC5D for adults whose relapsed or refractory multiple myeloma has spread outside the bone marrow.

  Recruiting Phase 1 Beijing GoBroad Hospital · Shanghai · NCT07003568

• Dual-target BCMA–CD19 CAR-T therapy for relapsed or refractory multiple myeloma with extramedullary disease

  This trial will try a CAR-T treatment that targets both BCMA and CD19 for adults whose relapsed or refractory multiple myeloma has spread outside the bone marrow.

  Recruiting Phase 1 Beijing GoBroad Hospital · Shanghai · NCT07003555

• Evaluating OL-108 for autoimmune diseases that have not responded to previous treatments

  This study is testing a new treatment called OL-108 to see if it can help people with autoimmune diseases that haven't improved with other therapies.

  Recruiting at 2 sites Phase 1 Beijing GoBroad Hospital · Beijing and 1 other locations · NCT06980597

• Umbilical cord blood CD19-BCMA CAR T cell treatment for refractory lupus nephritis, systemic sclerosis, and Sjögren's with pulmonary hypertension

  This treatment will try umbilical cord blood–derived CD19‑BCMA CAR T cells in people with refractory lupus nephritis, systemic sclerosis, or primary Sjögren's syndrome with pulmonary hypertension who have not responded to standard therapies.

  Recruiting Phase 1/2 Beijing GoBroad Hospital · Beijing, Beijing Municipality · NCT06947473

• CD19-BCMA CAR T cell therapy for difficult-to-treat autoimmune diseases

  This study is testing a new CAR T cell therapy to see if it can help people with tough autoimmune diseases like lupus nephritis, systemic sclerosis, and Sjogren's syndrome who haven't found relief with regular treatments.

  Recruiting Phase 1/2 Beijing GoBroad Hospital · Beijing, China,Beijing · NCT06947460

• CD7 CAR T-Cell Therapy for T-Cell Lymphomas

  This study is testing a new CAR T-cell therapy for people with T-cell lymphomas that haven't responded to regular treatments to see if it is safe and effective.

  Recruiting at 4 sites Phase 1/2 Beijing GoBroad Hospital · Beijing, Beijing Municipality and 3 other locations · NCT06925464

• Treatment of relapsed/refractory acute B-cell leukemia with BiTE-EV

  This study is testing a new treatment called BiTE-EV to see if it can help adults with relapsed or refractory acute B-cell leukemia feel better.

  Recruiting Early Phase 1 Beijing GoBroad Hospital · Beijing · NCT06890494

• CT1190B treatment for severe lupus and scleroderma

  This study is testing a new CAR-T cell therapy called CT1190B to see if it can help adults with severe lupus or scleroderma who haven't responded to other treatments.

  Recruiting Phase 1 Beijing GoBroad Hospital · Beijing, Beijing Municipality · NCT06822881

• Exploring CT1190B for treating relapsed B-cell Non-Hodgkin Lymphoma

  This study is testing a new CAR-T cell therapy called CT1190B to see if it can safely help people with relapsed B-cell Non-Hodgkin Lymphoma.

  Recruiting Phase 1 Beijing GoBroad Hospital · Beijing, Beijing Municipality · NCT06822868

• Using CD19 CAR T cells to treat difficult autoimmune diseases

  This study is testing if a new treatment using CD19 CAR T cells can help people with tough autoimmune diseases like lupus feel better.

  Recruiting Phase 1/2 Beijing GoBroad Hospital · Beijing, Beijing Municipality · NCT06688799

• JCXH-213 for relapsed or refractory CD19-positive B‑cell non-Hodgkin lymphoma

  This study will try an in‑body mRNA‑LNP CAR therapy called JCXH-213 in adults with relapsed or refractory CD19-positive B‑cell non‑Hodgkin lymphoma to see if it is safe and can shrink tumors.

  Recruiting Beijing GoBroad Hospital · Beijing · NCT06618313

• Using CD19 CAR T cells to treat refractory systemic lupus erythematosus

  This study is testing if a new type of immune cell therapy can help people with hard-to-treat systemic lupus erythematosus feel better.

  Recruiting Phase 1/2 Beijing GoBroad Hospital · Beijing, Beijing Municipality · NCT06585514

• ADCs plus adebrelimab in HER2-negative advanced breast cancer

  This study tests three antibody-drug conjugates (SHR-A1811, SHR-A1921, SHR-A2102) combined with adebrelimab to see if they help people with HER2-negative advanced breast cancer who have already tried other drugs.

  Recruiting Phase 2 Beijing GoBroad Hospital · Beijing, Beijing Municipality · NCT06433609

• CIK cell therapy for relapsed or refractory B‑cell acute lymphoblastic leukemia with early CAR‑T dysfunction

  We are testing whether giving regular or mRNA‑modified CIK cells helps children and young adults with relapsed or refractory B‑cell ALL who show early CAR‑T cell exhaustion stay free of relapse or disease progression longer.

  Recruiting Beijing GoBroad Hospital · Beijing, Beijing Municipality · NCT06389305

• Comparing CD19 and CD22 CAR T-cell therapies for treating relapsed B-ALL

  This study is testing whether giving patients with relapsed B-cell Acute Lymphoblastic Leukemia two different types of CAR T-cell therapies one after the other works better than just one type followed by a stem cell transplant.

  Recruiting Beijing GoBroad Hospital · Beijing, Beijing Municipality · NCT06343090

• Optimized CAR T Therapy for Acute Myeloid Leukaemia

  This study is testing a new CAR T therapy to see if it can safely help people with tough cases of acute myeloid leukaemia get better.

  Recruiting Phase 1 Beijing GoBroad Hospital · Shanghai, Shanghai Municipality and 3 other locations · NCT06326021

• Donor-derived CD19 CAR T cells with allo‑HSCT followed by donor-derived CD22 CAR T cells for relapsed/refractory B‑ALL

  This study tests donor-derived CD19 CAR T cells followed by an allogeneic stem‑cell transplant and sequential donor-derived CD22 CAR T cells in children and adolescents (1–18 years) with relapsed or refractory CD19+/CD22+ B‑ALL who cannot provide their own cells.

  Recruiting Phase 1 Beijing GoBroad Hospital · Beijing, Beijing Municipality · NCT06326008

• CD5 CAR T-cell therapy for relapsed or refractory T-cell malignancies

  This study is testing a new CAR T-cell therapy for people with hard-to-treat T-cell cancers to see if it is safe and how well it works.

  Recruiting at 3 sites Phase 1/2 Beijing GoBroad Hospital · Beijing, Beijing Municipality and 3 other locations · NCT06316856

• CD7 CAR-T therapy for patients with relapsed or refractory T-cell malignancies

  This study is testing a new type of CAR-T therapy for people with T-cell leukemia that hasn't responded to other treatments to see if it can help them feel better.

  Recruiting at 3 sites Phase 1/2 Beijing GoBroad Hospital · Beijing, Beijing Municipality and 3 other locations · NCT06316427

Quick answers

How many clinical trials run by Beijing GoBroad Hospital are recruiting right now?

27, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

All of them have sites in China. Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1/2: 9, Phase 1: 9, Early Phase 1: 3, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →